Skip to main content
    S

    Sensus Healthcare Inc (SRTS)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $2.34
    +0.02 (+0.65%)

    Market Cap: $38.27M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Sensus Healthcare Inc (SRTS) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Sensus Healthcare (SRTS) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Sensus Healthcare reported EPS of -$0.09, below the -$0.04 estimate. It beat the EPS estimate in 1 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    56%(22/39)
    Avg Surprise
    +1.20%

    Upcoming Estimates

    Reports Feb 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.02
    Range-$0.04 - $0.01
    6 analysts
    Revenue Consensus
    $6.82M
    Range$4.51M - $8.19M
    6 analysts

    Next Report

    SRTS has an expected report date of Feb 10, 2027.

    SRTS Earnings Call

    The latest SRTS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, SRTS beat 22, missed 15 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $6.00M, down 12.8% from $6.88M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.09-$0.04-$0.08 - $0.02-107.85%MissN/A30 up, 0 downNov 12, 2026$6.00M
    Jun 30, 2026-$0.18-$0.11-$0.15 - -$0.09-63.64%MissN/A30 up, 2 downAug 13, 2026$2.29M
    Mar 31, 2026-$0.16-$0.11-$0.12 - -$0.10-45.45%MissN/A30 up, 2 downMay 7, 2026$3.39M
    Dec 31, 2025-$0.19-$0.05-$0.06 - -$0.05-280.00%Miss-311.1%20 up, 0 downFeb 12, 2026$4.94M
    Sep 30, 2025-$0.06-$0.11-$0.13 - -$0.08+45.45%Beat-185.7%30 up, 0 downNov 6, 2025$6.88M
    Jun 30, 2025-$0.06$0.01-$0.01 - $0.03-700.00%Miss-160.0%31 up, 3 downAug 7, 2025$7.32M
    Mar 31, 2025-$0.16$0.04-$0.01 - $0.04-500.00%Miss-214.3%40 up, 1 downMay 15, 2025$8.34M
    Dec 31, 2024$0.09$0.12$0.09 - $0.14-25.00%Miss-65.4%40 up, 2 downFeb 5, 2025$13.07M
    Sep 30, 2024$0.07-$0.01-$0.02 - -$0.01+800.00%BeatN/A21 up, 0 downNov 14, 2024$8.84M
    Jun 30, 2024$0.10$0.03$0.02 - $0.03+233.33%BeatN/A31 up, 0 downAug 8, 2024$9.24M
    Mar 31, 2024$0.14-$0.04-$0.07 - -$0.04+450.00%BeatN/A20 up, 0 downMay 9, 2024$10.66M
    Dec 31, 2023$0.26$0.14$0.04 - $0.19+85.71%Beat+52.9%54 up, 0 downFeb 8, 2024$12.57M
    Sep 30, 2023-$0.09-$0.02-$0.05 - $0.03-350.00%Miss-181.8%50 up, 0 downNov 9, 2023$3.90M
    Jun 30, 2023-$0.02-$0.08-$0.11 - -$0.03+75.00%Beat-109.5%50 up, 0 downAug 3, 2023$4.53M
    Mar 31, 2023-$0.12$0.13$0.07 - $0.17-192.31%Miss-112.4%50 up, 0 downMay 3, 2023$3.41M
    Dec 31, 2022$0.17$0.23$0.19 - $0.30-26.09%Miss-46.9%53 up, 0 downFeb 9, 2023$13.10M
    Sep 30, 2022$0.11$0.13$0.05 - $0.19-15.38%Miss+1000.0%50 up, 0 downNov 3, 2022$9.01M
    Jun 30, 2022$0.21$0.13N/A+61.54%BeatN/AN/A0 up, 0 downAug 4, 2022$12.08M
    Mar 31, 2022$0.97$0.40$0.03 - $0.80+142.50%BeatN/A50 up, 0 downMay 5, 2022$10.34M
    Dec 31, 2021$0.32$0.16$0.10 - $0.22+100.00%Beat+1500.0%60 up, 0 downFeb 10, 2022$13.03M
    Sep 30, 2021$0.01-$0.02-$0.07 - $0.02+150.00%BeatN/A6N/ANov 4, 2021$5.53M
    Jun 30, 2021-$0.02-$0.06-$0.08 - -$0.04+66.67%BeatN/A6N/AAug 5, 2021$5.42M
    Mar 31, 2021-$0.07-$0.11-$0.13 - -$0.04+36.36%BeatN/A6N/AMay 6, 2021$3.07M
    Dec 31, 2020$0.02-$0.11-$0.17 - -$0.08+118.18%Beat-66.7%6N/AFeb 25, 2021$5.09M
    Sep 30, 2020-$0.14-$0.14-$0.16 - -$0.110.00%In lineN/A6N/ANov 5, 2020$1.62M
    Jun 30, 2020-$0.16-$0.19-$0.23 - -$0.13+15.79%Beat-1700.0%6N/AAug 6, 2020$1.18M
    Mar 31, 2020-$0.22-$0.07-$0.12 - -$0.03-214.29%MissN/A6N/AMay 7, 2020$1.68M
    Dec 31, 2019$0.06$0.03$0.00 - $0.06+100.00%Beat+500.0%6N/AFeb 13, 2020$8.51M
    Sep 30, 2019-$0.04-$0.03-$0.07 - $0.02-33.33%MissN/A6N/ANov 6, 2019$5.84M
    Jun 30, 2019$0.01-$0.04-$0.14 - $0.00+125.00%BeatN/A7N/AAug 8, 2019$7.48M
    Mar 31, 2019-$0.13-$0.03-$0.06 - $0.00-333.33%MissN/A7N/AMay 9, 2019$5.44M
    Dec 31, 2018$0.01-$0.01-$0.04 - $0.03+200.00%BeatN/A7N/AFeb 14, 2019$8.08M
    Sep 30, 2018-$0.03-$0.06-$0.12 - -$0.04+50.00%BeatN/A6N/ANov 1, 2018$6.33M
    Jun 30, 2018-$0.04-$0.05-$0.08 - -$0.03+20.00%BeatN/A4N/AAug 2, 2018$6.06M
    Mar 31, 2018-$0.08-$0.03-$0.10 - -$0.03-166.67%MissN/A2N/AMay 3, 2018$5.96M
    Dec 31, 2017-$0.03-$0.08-$0.08 - -$0.08+62.50%Beat-1300.0%2N/AFeb 1, 2018$6.47M
    Sep 30, 2017-$0.07-$0.07N/A0.00%In lineN/AN/AN/ANov 2, 2017$4.80M
    Jun 30, 2017-$0.06-$0.13N/A+53.85%BeatN/AN/AN/AAug 3, 2017$4.97M
    Mar 31, 2017-$0.12$0.01N/AN/AN/AN/AN/AN/AMay 4, 2017$4.35M
    Dec 31, 2016$0.00-$0.03N/A+108.33%BeatN/AN/AN/AFeb 2, 2017$4.88M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.47, after $0.40 the year before. It was -$0.03 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.47-217.5%
    Dec 31, 2024$0.40+1233.3%
    Dec 31, 2023$0.03-97.9%
    Dec 31, 2022$1.46+508.3%
    Dec 31, 2021$0.24N/A
    Dec 31, 2020-$0.50N/A
    Dec 31, 2019-$0.10N/A
    Dec 31, 2018-$0.14N/A
    Dec 31, 2017-$0.28N/A
    Dec 31, 2016-$0.03N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,200 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,1557
    2026Q2Jun 30, 20263,5017
    2026Q1Mar 31, 20263,8696
    2025Q4Dec 31, 20253,5837
    2025Q3Sep 30, 20254,9058
    2025Q2Jun 30, 20255,1098
    2025Q1Mar 31, 20254,3829
    2024Q4Dec 31, 20245,2428

    2026Q3 Earnings Call

    Opening remarks

    Leigh Salvo Investor Relations Thank you. Good afternoon, and thank you all for joining today's call to discuss Sensus Healthcare's Third Quarter 2026 Financial Results. Joining me from Sensus are Joe Sardano, Chairman and Chief Executive Officer; Michael Sardano, President, Chief Commercial Officer and General Counsel; and Javier Rampolla, Chief Financial Officer. As a reminder, some of the matters that will be discussed during today's call contain forward-looking statements within the meaning of federal securities laws. All statements other than historical facts that address activities Sensus Healthcare assumes, plans, expects, believes, intends or anticipates, and other similar expressions, will, should or may occur in the future are forward-looking statements. The forward-looking statements are management's beliefs based on currently available information as of the date of this conference call, November 12, 2026. Sensus Healthcare undertakes no obligation to revise or update any forward-looking statements, except as required by law. All forward-looking statements are subject to risks and uncertainties as described in the company's Forms 10-K, 10-Q and other SEC filings. During today's call, references will be made to certain non-GAAP financial measures. Sensus believes these measures provide useful information for investors, yet they should not be considered a substitute for GAAP, nor should they be reviewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in today's press release. With that, I'd like to turn the call over to Joe Sardano. Joe?

    Joseph Sardano Chairman and Chief Executive Officer Thank you, Leigh, and good afternoon, everyone. At the beginning of this year, we laid out five priorities for Sensus: educate the market about SRT and the new reimbursement environment, accelerate customer adoption, expand recurring revenue opportunities, broaden our commercial reach and move Sensus towards sustainable profitability. Those priorities have not changed. I want to take a minute to start with the bigger picture because it's important to understand what we're building at Sensus. For decades, surgery, including Mohs surgery, has been a primary treatment option for non-melanoma skin cancer. Mohs is an effective and well-established procedure, but surgery isn't the right choice for every patient. Many patients want to avoid cutting, stitches, scarring or the recovery associated with surgery, particularly when the cancer is in a cosmetically sensitive area. SRT gives physicians and patients another option. It's a noninvasive treatment that can address certain skin cancers without surgical excision. We believe patients should understand their treatment choices and physicians should have the technology to offer those choices when clinically appropriate. That's our vision for Sensus. We're not simply selling equipment. We're working to make SRT a more widely understood and accessible treatment option. And we're making progress.

    Frequently Asked Questions About SRTS

    When is Sensus Healthcare's next earnings date?

    Sensus Healthcare's next earnings report is expected for Feb 10, 2027.

    Did SRTS beat earnings estimates last quarter?

    No. Sensus Healthcare reported EPS of -$0.09 for the quarter ended Sep 30, 2026, below the -$0.04 estimate by 107.85%.

    What EPS do analysts expect from SRTS next quarter?

    The consensus EPS estimate for Sensus Healthcare for the quarter ending Dec 31, 2026 is -$0.02 from 6 analysts, with estimates from -$0.04 to $0.01.

    How often does SRTS beat earnings estimates?

    Sensus Healthcare beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -209.56%.